Wound Management Technologies (WNDM) has received an initial order of $2m for its CellerateRX from Orlando-based Marketing Media Enterprises (MME).
CellerateRX’s activated collagen (approximately 1/100th the size of native collagen) delivers the essential benefits of collagen to a wound immediately.
The woundcare product is used for all wound types except for 3rd degree burns and is available in both powder and gel form.
WNDM chairman and CEO Scott Haire said the agreement facilitates the growth of revenues without having the large sales force most companies require to gain market share in the wound care space.
President Deborah Jenkins Hutchinson said the need for effective wound care treatment has never been greater, as our population ages and type 2 diabetes affects more and more Americans.